Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA5A | P35218 | 1/20 | 0.68 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | GPR3 | P46089 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | BLM | P54132 | 2/20 | 0.47 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.47 |
| ▸ | GMNN | O75496 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.47 |
| ▸ | MTOR | P42345 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | GABRP | O00591 | 3/20 | 0.47 |
| ▸ | GABRD | O14764 | 3/20 | 0.47 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1336334 | 0.81 | CA5A (1.00) | CA5AHSD17B10ALDH1A1GPR3LMNA | |
| SCHEMBL29623886 | 0.81 | CA5A (1.00) | CA5AHSD17B10ALDH1A1GPR3LMNA | |
| SCHEMBL675919 | 0.79 | KDM4E (0.54) | CA5AHSD17B10LMNAKDM4ECYP1A2 | |
| SCHEMBL23319574 | 0.77 | CA5A (0.62) | CA5AHSD17B10ALDH1A1GPR3LMNA | |
| SCHEMBL676055 | 0.77 | CA5A (0.62) | CA5AHSD17B10ALDH1A1GPR3LMNA | |
| SCHEMBL38654007 | 0.77 | CA5A (0.62) | CA5AHSD17B10ALDH1A1GPR3LMNA | |
| SCHEMBL25694430 | 0.77 | CA5A (0.62) | CA5AHSD17B10ALDH1A1GPR3LMNA | |
| SCHEMBL31285916 | 0.77 | CA5A (0.57) | CA5AHSD17B10ALDH1A1GPR3LMNA | |
| SCHEMBL29475846 | 0.77 | MAPT (0.62) | MAPTACHE | |
| SCHEMBL17967678 | 0.77 | MAPT (0.58) | ALDH1A1KDM4EGABRPGABRDGABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250042902-A1 | TRICYCLIC CRBN LIGANDS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-02-06 | — | — | US | disclosed |
| US-11897882-B2 | Tricyclic crbn ligands and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2024-02-13 | — | — | US | disclosed |
| US-11665957-B2 | Organometallic compound, organic light-emitting device including the organometallic compound, and diagnostic composition including the organometallic compound | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2023-05-30 | — | — | US | disclosed |
| WO-2023071147-A1 | BINUCLEAR METAL PLATINUM COMPLEX AND ORGANIC ELECTROLUMINESCENT DEVICE | 深圳大学 | 2023-05-04 | — | — | WO | disclosed |
| US-20220306631-A1 | TRICYCLIC CRBN LIGANDS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2022-09-29 | — | — | US | disclosed |
| US-11325908-B2 | CaMKII inhibitors and uses thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2022-05-10 | — | — | US | disclosed |
| US-11292792-B2 | Tricyclic CRBN ligands and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-04-05 | — | — | US | disclosed |
| EP-3189052-B1 | CAMKII INHIBITORS AND USES THEREOF | UNIV JOHNS HOPKINS (US) | 2021-11-03 | — | — | EP | disclosed |
| EP-3817748-A1 | TRICYCLIC CRBN LIGANDS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2021-05-12 | — | — | EP | disclosed |
| US-20200385383-A1 | CaMKII INHIBITORS AND USES THEREOF | ALLOSTEROS THERAPEUTICS, INC. | 2020-12-10 | — | — | US | disclosed |
| US-20170062738-A1 | Organometallic Complex, Light-Emitting Element, Light-Emitting Device, Electronic Device, and Lighting Device | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2017-03-02 | — | — | US | disclosed |
| WO-2016037106-A1 | CaMKII INHIBITORS AND USES THEREOF | ALLOSTEROS THERAPEUTICS, INC (US) | 2016-03-10 | — | — | WO | disclosed |
| US-20160024078-A1 | CaMKII INHIBITORS AND USES THEREOF | ALLOSTEROS THERAPEUTICS, INC. (US) | 2016-01-28 | — | — | US | disclosed |
| EP-2964225-A1 | CaMKII INHIBITORS AND USES THEREOF | Allosteros Therapeutics Inc. (US) | 2016-01-13 | — | — | EP | disclosed |
| US-8895744-B2 | Alfa-carboline inhibitors of NPM-ALK, RET, and Bcr-Abl | UNIVERSITA' DEGLI STUDI DI MILANO-BICOCCA (IT) | 2014-11-25 | — | — | US | disclosed |
| WO-2014138212-A1 | CaMKII INHIBITORS AND USES THEREOF | ALLOSTEROS THERAPEUTICS, INC. (US) | 2014-09-12 | — | — | WO | disclosed |
| US-20110281862-A1 | ALFA-CARBOLINE INHIBITORS OF NPM-ALK, RET, AND BCR-ABL | UNIVERSITA' DEGLI STUDI DI MILANO - BICOCCA (IT) | 2011-11-17 | — | — | US | disclosed |
| CN-102203092-A | Alfa-carboline inhibitors of npm-alk, ret, and bcr-abl | UNIV DEGLI STUDI MILANO | 2011-09-28 | — | — | CN | disclosed |
| WO-2010025872-A2 | ALFA-CARBOLINE INHIBITORS OF NPM-ALK, RET, AND BCR-ABL | UNIVERSITA' DEGLI STUDI DI MILANO-BICOCCA (IT) | 2010-03-11 | — | — | WO | disclosed |
| EP-2161271-A1 | Alpha-carboline inhibitors of NMP-ALK, RET, and Bcr-Abl | Università Degli Studi Di Milano - Bicocca (IT) | 2010-03-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11325908-B2 | CaMKII inhibitors and uses thereof | CAMK2G, CAMK2B, CAMK1 | CA5A 674/4885HSD17B10 3681/4885ALDH1A1 4581/4885 |
| US-11292792-B2 | Tricyclic CRBN ligands and uses thereof | CRBN, CRKL, CUL4A | CA5A 2374/4885HSD17B10 2876/4885ALDH1A1 4128/4885 |
| US-11665957-B2 | Organometallic compound, organic light-emitting device including the organometallic compound, and diagnostic composition including the organometallic compound | C5, CYC1, CYBA | CA5A 628/4885HSD17B10 3626/4885ALDH1A1 1051/4885 |
| US-11897882-B2 | Tricyclic crbn ligands and uses thereof | CRBN, CRKL, CUL4A | CA5A 2374/4885HSD17B10 2876/4885ALDH1A1 4128/4885 |
| US-20250042902-A1 | TRICYCLIC CRBN LIGANDS AND USES THEREOF | CRBN, CRKL, CUL4A | CA5A 2374/4885HSD17B10 2876/4885ALDH1A1 4128/4885 |
| US-20110281862-A1 | ALFA-CARBOLINE INHIBITORS OF NPM-ALK, RET, AND BCR-ABL | ALK, BCR, NPM1 | CA5A 1904/4885HSD17B10 2928/4885ALDH1A1 749/4885 |
| US-20170062738-A1 | Organometallic Complex, Light-Emitting Element, Light-Emitting Device, Electronic Device, and Lighting Device | PPOX, LAGE3, PDCD1LG2 | CA5A 3485/4885HSD17B10 3403/4885ALDH1A1 1724/4885 |
| US-20160024078-A1 | CaMKII INHIBITORS AND USES THEREOF | CAMK2G, CAMK2B, CAMK1 | CA5A 674/4885HSD17B10 3681/4885ALDH1A1 4581/4885 |
| US-20220306631-A1 | TRICYCLIC CRBN LIGANDS AND USES THEREOF | CRBN, CRKL, CUL4A | CA5A 2374/4885HSD17B10 2876/4885ALDH1A1 4128/4885 |
| US-20200385383-A1 | CaMKII INHIBITORS AND USES THEREOF | CAMK2G, CAMK2B, CAMK1 | CA5A 674/4885HSD17B10 3681/4885ALDH1A1 4581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.